CASI Pharmaceuticals (FRA:ENM) Dividends per Share: €0.00 (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ENM CASI Pharmaceuticals Inc FRA:ENM
29 GF Score
Price €1.54
GF Value €11.78
! 5 Warning Signs
View Full Analysis

What is CASI Pharmaceuticals Dividends per Share?

CASI Pharmaceuticals FRA:ENM 29 Dividends per Share is €0.00 as of Dec. 2025. GuruFocus rates FRA:ENM with a GF Score™ of 29/100 and a GF Value™ of €11.78. The stock has 5 warning signs investors should review.

CASI Pharmaceuticals's dividends per share for the three months ended in Dec. 2025 was €0.00. Its dividends per share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00. Its Dividend Payout Ratio for the three months ended in Dec. 2025 was 0.00. As of today, CASI Pharmaceuticals's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

CASI Pharmaceuticals  (FRA:ENM) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

CASI Pharmaceuticals's Dividend Payout Ratio for the quarter that ended in Dec. 2025 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Dec. 2025 )/ EPS without NRI (Q: Dec. 2025 )
=0/ -0.271
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CASI Pharmaceuticals Dividends per Share Related Terms

CASI Pharmaceuticals Dividends per Share Historical Data

* Premium members only.

The historical data trend for CASI Pharmaceuticals's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CASI Pharmaceuticals Dividends per Share Chart

CASI Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Dividends per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CASI Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Dividends per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:ENM vs ITRMF, OGEN, AZTR: Dividends per Share Comparison

For the Biotechnology subindustry, CASI Pharmaceuticals's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CASI Pharmaceuticals Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where CASI Pharmaceuticals's Dividend Yield % falls into.


FRA:ENM
29GF Score
CASI Pharmaceuticals Inc FRA:ENM
Dividends per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CASI Pharmaceuticals Dividends per Share Calculation

Dividends paid to per common share.

Frequently Asked Questions Learn more about Dividends per Share →
What does a Dividends per Share of €0.00 mean?
CASI Pharmaceuticals (FRA:ENM) has a Dividends per Share of €0.00 as of Dec. 2025. Dividends per share represents the per-share amount paid as dividends. View historical data on CASI Pharmaceuticals and its competitors.
Is CASI Pharmaceuticals' Dividends per Share too high?
CASI Pharmaceuticals' current Dividends per Share is €0.00. Overall, CASI Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does CASI Pharmaceuticals' Dividends per Share compare to ITRMF and OGEN?
CASI Pharmaceuticals' Dividends per Share of €0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividends per Share for a Biotechnology company?
A good Dividends per Share depends on the Biotechnology industry context. However, Dividends per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividends per Share mean?
A high Dividends per Share can signal that a stock is expensive relative to its fundamentals. Dividends per share represents the per-share amount paid as dividends. View historical data on CASI Pharmaceuticals and its competitors. CASI Pharmaceuticals's current Dividends per Share is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CASI Pharmaceuticals stock overvalued right now?
CASI Pharmaceuticals (FRA:ENM) has a current Dividends per Share of €0.00. The stock's GF Value™ is €11.78, compared to a current price of €1.54 — trading 86.9% below its estimated fair value. The current Dividends per Share is €0.00. CASI Pharmaceuticals' overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividends per Share calculated?
Dividends per Share is calculated from a company's financial statements. For CASI Pharmaceuticals (FRA:ENM), the current Dividends per Share is €0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CASI Pharmaceuticals (FRA:ENM) Overvalued in 2026?

Based on GuruFocus' analysis, CASI Pharmaceuticals stock appears to be undervalued. The current stock price of €1.54 is trading 86.9% below its estimated GF Value™ of €11.78.

Key valuation signals for FRA:ENM:

  • Dividends per Share: €0.00
  • GF Value™: €11.78 vs. price of €1.54 (86.9% below fair value)
  • GF Score™: 29/100 with 5 warning signs

No single metric tells the full story. See the FRA:ENM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CASI Pharmaceuticals Business Description

Other Exchanges CASIF:USA
Address Jianguo Road, No. 81, Room 1701-1702, China Central Office Tower 1, Huamao Office Building, Chaoyang District, Beijing, CHN, 100025
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
29GF Score

Get the complete analysis for FRA:ENM

Dividends per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.54
Price
€11.78
GF Value